Exome Sequencing Enhances Screening for Familial Hypercholesterolemia Within a Multi-Site Healthcare System
Authors:
- N. Jewel SamadderNSN. Jewel Samadder
- Mariah SchroederMSMariah Schroeder
- Molly M. VossMVMolly M. Voss
- Fadi ShamounFSFadi Shamoun
- Iftikhar KulloIftikhar Kullo
- Timothy B. CurryTCTimothy B. Curry
- Elisa J.F. HouwinkEHElisa J.F. Houwink
- Michelle L. BublitzMBMichelle L. Bublitz
- Lorelei A. BandelLBLorelei A. Bandel
- Sebastian M. ArmasuSASebastian M. Armasu
- Robert A. VierkantRVRobert A. Vierkant
- Matthew J. FerberMFMatthew J. Ferber
- 1 December 2025
- journal article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (6) , e005174
Abstract
BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that increases risk for premature coronary artery disease and has accessible and effective interventions. The Dutch lipid clinic network is currently the most used diagnostic criterion; however, genetic sequencing provides a definitive diagnosis of FH. The goals of this study were to determine whether germline genetic screening using exome sequencing could be used to efficiently identify individuals who were genotype positive for FH. METHODS: Participants were recruited from 3 geographically and racially diverse sites in the United States (Rochester, MN; Phoenix, AZ; and Jacksonville, FL). Participants underwent Exome+ sequencing (dba Helix, San Mateo, CA) and return of results for specific genetic findings in APOB , LDLR , or PCSK9 . A chart review was performed to collect demographics, personal, and family cardiovascular history. RESULTS: At the time of the study, 84 413 participants were enrolled in the Tapestry study. Annotation and interpretation of all variants in genes for FH resulted in the identification of 419 likely pathogenic and pathogenic variants (prevalence, 0.50%), which included 116 APOB , 298 LDLR , and 5 PCSK9 . Sixty-six percent were female, the mean body mass index was 27.3, with 12.3% reporting a history of diabetes. Hypertriglyceridemia (≥150 mg/dL) was present in 39.5% and reduced HDL (<50 mg/dL) was present in 56.7% of patients. 27.5% of patients were not on cholesterol-lowering medications, and only 10% of FH carriers were at goal low-density lipoprotein cholesterol levels. A history of coronary artery disease was reported in 22.4% of the cohort. Nearly 90% of these participants were newly diagnosed carriers of FH. Only 30.8% of confirmed genetic diagnoses of FH satisfied clinical (Dutch lipid clinic network) criteria for a diagnosis. CONCLUSIONS: Our results emphasize the need for wider utilization of germline genetic sequencing for enhanced screening and detection of individuals who have familial hypercholesterolemia. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05212428.Keywords
This publication has 23 references indexed in Scilit:
- Mayo Clinic Tapestry StudyMayo Clinic Proceedings, 2024
- Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United StatesGenetics in Medicine, 2022
- Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United StatesJAMA Network Open, 2020
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer SyndromesAmerican Journal of Gastroenterology, 2015
- Familial hypercholesterolemia: a missed opportunity in preventive medicineNature Clinical Practice Cardiovascular Medicine, 2007
- Mechanisms of Disease: genetic causes of familial hypercholesterolemiaNature Clinical Practice Cardiovascular Medicine, 2007
- Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemiaAtherosclerosis, 2004
- A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemiaAtherosclerosis, 2003
- Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular geneticsThe American Journal of Cardiology, 1993